Literature DB >> 25458044

Role of cytokine gene (interferon-γ, transforming growth factor-β1, tumor necrosis factor-α, interleukin-6, and interleukin-10) polymorphisms in the risk of oral precancerous lesions in Taiwanese.

Han-Jen Hsu1, Yi-Hsin Yang2, Tien-Yu Shieh3, Chung-Ho Chen4, Yu-Hsun Kao1, Chia-Fu Yang1, Edward Cheng-Chuan Ko5.   

Abstract

Oral squamous cell carcinoma can be preceded by some benign oral lesions with malignant potential, including leukoplakia, erythroplakia, oral lichen planus, and oral submucous fibrosis. There are different degrees of inflammatory cells infiltration in histopathology. Inflammatory cytokines may play a pathogenic role in the development of oral precancerous lesions (OPCLs). Genetic polymorphisms of cytokine-encoding genes are known to predispose to malignant disease. We hypothesized that the risk of OPCLs might be associated with cytokine gene polymorphisms of interferon (IFN)-γ, transforming growth factor (TGF)-β1, tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-10. In the present study, 42 OPCL patients and 128 controls were analyzed for eight polymorphisms in five different cytokine genes [IFN-γ (+874 T/A), TGF-β1 (codons 10 T/C and 25 G/C), TNF-α (-308 G/A), IL-6 (-174 G/C), and IL-10 (-1082 A/G, -819 T/C, and -592 A/C)]. Cytokine genotyping was determined by the polymerase chain reaction sequence-specific primer technique using commercial primers. Allele and genotype data were analyzed for significance of differences between cases and controls using the Chi-square (χ(2)) test. Two-sided p < 0.05 were considered to be statistically significant. A series of multivariate logistic regression models, adjusted for age, sex, betel quid chewing, alcohol consumption, and smoking, was constructed in order to access the contribution of homozygous or heterozygous variant genotypes of polymorphisms. The TNF-α (-308) polymorphism was significantly associated with OPCLs. There were significant differences in the distribution of AA, GA, and GG genotypes between OPCL patients and controls (p = 0.0004). Patients with the AA or GA genotype had a 3.63-fold increased risk of OPCLs. The TGF-β1 (codon 10 and 25) polymorphism was also significantly associated with OPCLs (p < 0.001). The IL-6 polymorphism was significantly associated with OPCLs. There are significant differences in the distribution of CC, GC, and GG genotypes between OPCL patients and controls (p < 0.001). Patients with the CC or GC genotype had a 35- or 20.59-fold increased risk of OPCLs. There were no significant differences in the distribution of IL-10 and IFN-γ genotypes between different groups of control individuals and OPCL patients. The IL-6, TGF-β1, and TNF-α gene polymorphisms may have a significant association with the development of OPCLs.
Copyright © 2014. Published by Elsevier Taiwan.

Entities:  

Keywords:  Interleukin-6; Oral precancerous lesions; Polymorphism; Transforming growth factor-β1; Tumor necrosis factor-α

Mesh:

Substances:

Year:  2014        PMID: 25458044     DOI: 10.1016/j.kjms.2014.09.003

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  15 in total

1.  Association between IL-10 gene polymorphisms and the risk of ischemic stroke in a Chinese population.

Authors:  Wen He; Haiyan Song; Lihong Ding; Cunbao Li; Lina Dai; Shang Gao
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  IL-10 -1082A/G, -592C/A, and -819T/C polymorphisms in association with lung cancer susceptibility: a meta-analysis.

Authors:  Liang Liu; Feng Zheng
Journal:  Onco Targets Ther       Date:  2016-10-07       Impact factor: 4.147

3.  Diagnostic value of high-frequency color Doppler ultrasonography examination in combination with anti-cyclic citrullinated peptide antibody testing in rheumatoid arthritis patients.

Authors:  Ming-Yu Wang; Xian-Bin Wang; Xue-Hui Sun; Feng-Li Liu; Sheng-Chuan Huang
Journal:  Exp Ther Med       Date:  2017-01-17       Impact factor: 2.447

Review 4.  Single nucleotide polymorphisms as markers of genetic susceptibility for oral potentially malignant disorders risk: Review of evidence to date.

Authors:  Krithiga Shridhar; Aastha Aggarwal; Gagandeep Kaur Walia; Smriti Gulati; A V Geetha; D Prabhakaran; Preet K Dhillon; Preetha Rajaraman
Journal:  Oral Oncol       Date:  2016-10       Impact factor: 5.337

5.  Association between polymorphisms in interleukins and oral lichen planus: A meta-analysis.

Authors:  Quan Shi; Tong Zhang; Na Huo; Yang Huang; Juan Xu; Hongchen Liu
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

6.  Meta-analysis of the role of IL-6 rs1800795 polymorphism in the susceptibility to prostate cancer: Evidence based on 17 studies.

Authors:  Tong-Zu Liu; Zhong-Qiang Guo; Ting Wang; Yue Cao; Di Huang; Xing-Huan Wang
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

7.  Association of Inflammation-Related Gene Polymorphisms With Susceptibility and Radiotherapy Sensitivity in Head and Neck Squamous Cell Carcinoma Patients in Northeast China.

Authors:  Ying Li; Li Zhu; Hongmin Yao; Ye Zhang; Xiangyu Kong; Liping Chen; Yingqiu Song; Anna Mu; Xia Li
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

8.  TNF-α, TNF-β and IL-10 gene polymorphism and association with oral lichen planus risk in Saudi patients.

Authors:  Maha Ali Al-Mohaya; Fahad Al-Harthi; Misbahul Arfin; Abdulrahman Al-Asmari
Journal:  J Appl Oral Sci       Date:  2015 May-Jun       Impact factor: 2.698

9.  Association of genetic polymorphisms in interferon-γ, interleukin-6 and transforming growth factor-β1 gene with oral lichen planus susceptibility.

Authors:  Maha Ali M Al-Mohaya; Lubna Al-Otaibi; Fahad Al-Harthi; Ebtissam Al Bakr; Misbahul Arfin; Abdulrahman Al-Asmari
Journal:  BMC Oral Health       Date:  2016-08-20       Impact factor: 2.757

10.  Association between TGF-β1 Polymorphisms and Head and Neck Cancer Risk: A Meta-Analysis.

Authors:  Quan Shi; Xing Wang; Chuan Cai; Shuo Yang; Na Huo; Hongchen Liu
Journal:  Front Genet       Date:  2017-11-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.